Antibodies hold promise as therapeutic agents. However, their tendency to aggregate poses significant challenges to drug development. In a groundbreaking study, researchers now provide novel insights into the structure formed due to 3D domain swapping of the antibody light chain, the part of the antibody contributing to antigen binding. Their findings are expected to lead to improvements in antibody quality and the development of novel drugs.
Antibodies hold promise as therapeutic agents. However, their tendency to aggregate poses significant challenges to drug development. In a groundbreaking study, researchers now provide novel insights into the structure formed due to 3D domain swapping of the antibody light chain, the part of the antibody contributing to antigen binding. Their findings are expected to lead to improvements in antibody quality and the development of novel drugs. Antibodies hold promise as therapeutic agents. However, their tendency to aggregate poses significant challenges to drug development. In a groundbreaking study, researchers now provide novel insights into the structure formed due to 3D domain swapping of the antibody light chain, the part of the antibody contributing to antigen binding. Their findings are expected to lead to improvements in antibody quality and the development of novel drugs.